• linkedin
  • Increase Font
  • Sharebar

    Data weigh neuromodulation’s impact on QoL at 3 years

    A new industry-funded study finds that sacral neuromodulation patients with urgency incontinence, urgency frequency, or both—almost all of whom were women—reported improvement in quality of life measures after 3 years of treatment. 

    Also from AUA 2016: How number of Peyronie’s Tx cycles affects outcomes

    The patients had failed an average of two medications, said lead author Karen Noblett, MD, of the University of California Riverside School of Medicine, Riverside. According to Dr. Noblett, the findings “suggest we probably should move to third-line therapies more quickly and not prescribe medication after medication if they’ve failed a couple.”

    The InterStim system (Medtronic, Minneapolis) is FDA-approved for urinary incontinence, urgency-frequency, urinary retention, and fecal incontinence.

    “It’s a third-line therapy after behavioral therapy and medications,” Dr. Noblett told Urology Times, and unique because patients can test the therapy over a trial period to see if it helps them. If the treatment works, then the device is implanted permanently in the body.

    “It’s a very minimally invasive outpatient procedure, done with just local anesthesia and IV sedation,” she said.

    Read: Enucleation for RCC yields multiple benefits

    The new study, presented at the AUA annual meeting in San Diego, is a retrospective sub-analysis of a 5-year prospective study into the use of tined leads to hold the device in tissue. This research satisfies the FDA’s request for post-approval analysis, she noted.

    Next: How patients fared

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results